[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"insulin-response\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:insulin-response":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100636573","a1-free-vs-conventional-milk-metabolic-response-study-100636573",false,"NCT07567443","A1-Free vs. Conventional Milk Metabolic Response Study","A Randomized Crossover Study Evaluating Postprandial Glucose and Insulin Responses to A1-Free and Conventional Milk With and Without a Delayed Lactose Challenge in Healthy Adults","Inclusion Criteria:\n\n* Ability\u002Fdesire to provide informed consent\n* Are between 18 and 65 years of age\n* Are generally healthy, with no known metabolic or gastrointestinal conditions that would affect digestion or metabolism\n* Are willing to consume milk-based beverages and lactose-containing drinks as part of the study\n* Are willing to fast overnight (approximately 10-12 hours) prior to study visits and follow study instructions (e.g., diet and activity restrictions)\n* Are willing to attend all study visits and complete all study procedures (blood draws, breath tests, urine samples, questionnaires)\n* Are able to understand and provide written informed consent in English.\n\nExclusion Criteria:\n\n* You have a known allergy to milk or dairy products\n* You are currently pregnant, planning to become pregnant, or breastfeeding\n* You currently smoke or have used tobacco or nicotine-containing products within the past 3 months\n* You have a history of excessive alcohol use within the past 30 days\n* You have been diagnosed with diabetes (Type 1 or Type 2), prediabetes, or other metabolic conditions that affect glucose or insulin responses (such as insulin resistance, metabolic syndrome, or polycystic ovary syndrome \\[PCOS\\])\n* You have a history of gastrointestinal conditions that may affect digestion or absorption (such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, celiac disease, or severe irritable bowel syndrome)\n* You have had gastrointestinal surgery that alters normal digestive function (such as bariatric surgery or gastric bypass)\n* You have other medical conditions that may affect digestion or interfere with study results (such as Past or present: Organ transplant, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, Celiac disease, chronic constipation, diverticulosis, inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), small intestine bacterial overgrowth syndrome (SIBO), gastroparesis, gastro-esophageal reflux disease (GERD), Irritable Bowel Syndrome (IBS) or any other medical condition with symptoms that could confound collection of adverse events.)\n* You have used medications or supplements known to affect glucose metabolism, digestion, or gastrointestinal function within the following timeframes prior to enrollment:\n* Within 4 weeks: insulin, metformin, GLP-1 receptor agonists, corticosteroids, digestive enzymes, fiber supplements, and all oral or IV antibiotics\n* Within 2 weeks: bismuth-containing compounds (e.g., Pepto-Bismol) and proton pump inhibitors or acid suppressors (e.g., omeprazole \\[Prilosec\\], lansoprazole \\[Prevacid\\], esomeprazole \\[Nexium\\], pantoprazole \\[Protonix\\], rabeprazole \\[Aciphex\\])\n* Within 1 week: laxatives and stool softeners (e.g., Miralax, Colace, senna, lactulose, Citrucel, Metamucil, Fibercon), probiotics and prebiotics, gastrointestinal motility agents (e.g., Reglan, Linzess, Amitiza), and antidiarrheal medications (e.g., loperamide \\[Imodium\\], Lomotil)\n* You have had a recent infection within the past 30 days\n* You have been diagnosed with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C\n* You are currently undergoing chemotherapy\n* Height: \\_\\_\\_ Weight: \\_\\_\\_ BMI: \\_\\_\\_ Weighing \\\u003C16.5 kg or Body mass index \\> 35 kg\u002Fm2\n* You have participated in another clinical trial or used an investigational product within the past 30 days\n* You have any other condition that, as determined by the study team, would make participation unsafe or interfere with study results",true,"ALL","18 Years","65 Years",{"count":21,"type":22},35,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study will examine how different types of milk affect blood sugar and insulin responses after eating. Specifically, the study compares milk that contains only A2 beta-casein protein (A1-free milk) to conventional milk, which contains both A1 and A2 proteins.\n\nParticipants will complete four study visits in which they will consume different milk-based beverages. These include lactose-containing milk and lactose-free milk followed by a lactose drink given later. Blood samples will be collected over several hours to measure glucose and insulin responses. Breath tests and questionnaires will also be used to assess digestion and gastrointestinal symptoms.\n\nThe goal of this study is to determine whether milk protein type influences metabolic responses and whether consuming lactose-free milk affects how the body processes lactose when it is consumed later.",[28,29,30,31],"Postprandial Glucose Response","Insulin Response","Lactose Digestion","Postprandial Metabolism",[33,34,35,36,37,38,39,40],"A1 beta-casein","A1-free milk","Postprandial glucose","Insulin response","Postprandial Glycemia","Digestive Kinetics","Lactose digestion","Metabolic response","NOT_YET_RECRUITING","2026-04-28",{"date":44,"type":45},"2026-05-05","ACTUAL",{"date":47,"type":22},"2026-06-15",{"date":49,"type":22},"2027-01-31",{"name":51,"class":52},"Purdue University","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100612498","advancing-precision-nutrition-wearable-technology-for-noninvasive-insulin-monitoring-100612498","NCT07254364","Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring","Inclusion criteria:\n\n* Age\n\n  * 18-30 years old\n  * 50-90 years old\n* BMI between 22 and 35 kg\u002Fm2\n* Ability to walk, sit down, and stand up (independently or with a walking assistance device)\n* Willingness to lay supine in bed for up to 9 hours\n* Willingness and ability to comply with the protocol\n\nExclusion criteria\n\n* Known allergy to any of the components of the meal or agents used for the application of the devices\n\n  * Sunflower oil\n  * Maltodextrin\n  * Whey protein\n  * Pilocarpine solutions\n* Established diagnosis and active treatment of chronic disease: insulin-dependent diabetes, active malignancy, heart failure, kidney disease, liver disease, HIV\u002FAIDS, asthma (moderate to severe), Hep (A, B, or C)\n* History of untreated metabolic disease including hepatic or renal disorder\n* Presence of acute illness or metabolically unstable chronic illness\n* Active dependence on alcohol or drugs\n* Use of a short course of oral corticosteroids within 4 weeks preceding study day\n* Current use of long-term oral corticosteroids\n* Presence of fever within the last 3 days\n* Planned elective surgery requiring 2 or more days of hospitalization during the entire study\n* (Possible) pregnancy (confirmed via urine pregnancy test for females 18-30 years)\n* Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject\n* Any condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient","90 Years",{"count":61,"type":22},32,[25],"Noninvasively monitoring insulin is crucial for advancing precision nutrition and promoting healthy living by enabling a deeper understanding of individual metabolic responses to dietary intake. Insulin is a key regulator of blood sugar and energy metabolism, and its dysregulation is linked to conditions such as diabetes, obesity, and metabolic syndrome. By noninvasively tracking insulin levels, individuals can gain real-time insights into how their body processes different foods, allowing for the personalization of diets to optimize metabolic health, manage weight, and reduce disease risk. This approach also empowers proactive lifestyle adjustments to maintain insulin sensitivity, improve glycemic control, and enhance overall well-being. Decentralized insulin quantification in biofluids, including saliva and serum, based on lateral flow assay or electrochemical sensor has been reported. However, these approaches have poor sensitivity and fail to quantify insulin with a high temporal resolution.",[29],"RECRUITING","2025-11-19",{"date":68,"type":45},"2025-11-28",{"date":70,"type":45},"2025-09-11",{"date":72,"type":22},"2026-12",{"name":74,"class":52},"Texas A&M University",1]